Cancer Care Ontario | Action Cancer Ontario

encorafenib - In combination with cetuximab or panitumumab in previously treated BRAF V600E-mutated metastatic colorectal cancer, according to clinical criteria

New Drug Funding Program

Cetuximab - In Combination with Encorafenib for Previously Treated Metastatic Colorectal Cancer

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

encorafenib,

cetuximab

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2020

Status: Current
ID: PET 2020-1
Version: N/A

Nov 2020

Guidelines and Advice

Enhancing Clinical Cancer Genetic Service Delivery in Ontario - Recommendations for a New Model of Care

Status: Current
Version: 1.0

Dec 1969

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Equitable.png

Erwinia asparaginase

eCCOOntarioHealthVirtualTownHall3.jpg

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines: January to June 2019

Vaping products including e-cigarettes

VENE+OBIN

EndometrioidOvarianCancerTreatmentPathwayMap_2020-01.pdf

ExplanatoryNotes

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2019

ENCO+CETU

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2020

Enhancing Clinical Cancer Genetic Service Delivery in Ontario - Recommendations for a New Model of Care

Pages